Core Viewpoint - A class action lawsuit has been filed against Canadian Imperial Bank of Commerce (CIBC) and Royal Bank of Canada (RBC) for allegedly defrauding investors by executing manipulative trades that artificially deflated the price of Quantum Biopharma Ltd. (Quantum) securities [1][3]. Summary by Sections Lawsuit Details - The lawsuit seeks to recover damages for alleged violations of federal securities laws on behalf of all individuals and entities that sold Quantum securities between January 6, 2021, and October 15, 2025, inclusive [2]. - The Complaint alleges that Defendants engaged in thousands of spoofed sell orders to create a false appearance of declining stock prices, deceiving investors into selling shares at artificially depressed prices [3]. Allegations Against Defendants - Defendants are accused of making materially false and misleading statements and failing to disclose manipulative trading practices [3]. - The manipulative orders were designed to induce investors to sell their shares at lower prices, after which the Defendants purchased shares at these artificially deflated levels to profit from the scheme [3]. Next Steps for Investors - Investors who suffered losses in Quantum have until February 23, 2026, to request to be appointed as lead plaintiff in the class action [4]. - Participation in any recovery does not require serving as lead plaintiff [4]. Legal Representation - Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful in the lawsuit [5]. - The firm has a history of recovering hundreds of millions of dollars for investors in securities fraud class actions [6].